Global RNA Based Therapeutics Market

RNA Based Therapeutics Comprehensive Study by Application (Cardiovascular, Kidney Diseases, Oncology, Infectious Diseases, Metabolic Disorders, Others), Technology (Inhibition, Microarrays, Labeling, Purification, QRT-PCR, RNA Interference (RNAi) Technologies, RNA Antisense Technologies), End User (Research, Therapeutics, Diagnosis) Players and Region - Global Market Outlook to 2026

RNA Based Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
RNA based therapeutics have generated significant attention in recent years owing to their potential to treat a variety of chronic diseases such as diabetes, cancer, tuberculosis, and some cardiovascular conditions and rare diseases, and address targets that have proven to be intractable to antibody and small-molecule methodologies. RNA based therapeutics are poised to become successful commercial products, but extensive adoption across the bio pharmaceutical industry will likely take a few more years.This growth is primarily driven by Increasing Strategic Alliances and Funding and Rising Prevalence of Chronic Diseases across the Globe.

Globally, a noticeable market trend is evident Technological Developments Driving the RNA Based Therapeutics . Major Players, such as Quark Pharmaceuticals, Inc. (Israel), Alnylam Pharmaceuticals, Inc. (United States), Dicerna Pharmaceuticals, Inc. (United States), Arbutus Biopharma (Canada), Benitec Biopharma Limited (Australia), Genzyme Corporation (United States), Silence Therapeutics PLC (United Kingdom), Sirnaomics, Inc. (United States), BioNTech AG (Germany) and CureVac AG (Germany) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 28 May, 2019 - Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, has announced that it has entered into a collaboration with Genomics England Limited for the investigation of novel targets involved in human disease.

Regulatory Insights:
On August 10, 2018, the U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in peripheral nerves, the heart and other organs. It is also the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.

Market Drivers
  • Increasing Strategic Alliances and Funding
  • Rising Prevalence of Chronic Diseases across the Globe

Market Trend
  • Technological Developments Driving the RNA Based Therapeutics
  • Growing Adoption of Virtual Drug Development Models

Restraints
  • Difficulties in Drug Delivery

Opportunities
Early Commercialization of Pipeline Therapeutics Assists to Gain Competitive Benefit
Challenges
Threat of Failure and High Cost of Research

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, RNA Based Therapeutics Study Sheds Light on
— The RNA Based Therapeutics Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the RNA Based Therapeutics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where RNA Based Therapeutics industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Cardiovascular
  • Kidney Diseases
  • Oncology
  • Infectious Diseases
  • Metabolic Disorders
  • Others
By Technology
  • Inhibition
  • Microarrays
  • Labeling
  • Purification
  • QRT-PCR
  • RNA Interference (RNAi) Technologies
  • RNA Antisense Technologies

By End User
  • Research
  • Therapeutics
  • Diagnosis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Strategic Alliances and Funding
      • 3.2.2. Rising Prevalence of Chronic Diseases across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Threat of Failure and High Cost of Research
    • 3.4. Market Trends
      • 3.4.1. Technological Developments Driving the RNA Based Therapeutics
      • 3.4.2. Growing Adoption of Virtual Drug Development Models
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global RNA Based Therapeutics, by Application, Technology, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global RNA Based Therapeutics (Value)
      • 5.2.1. Global RNA Based Therapeutics by: Application (Value)
        • 5.2.1.1. Cardiovascular
        • 5.2.1.2. Kidney Diseases
        • 5.2.1.3. Oncology
        • 5.2.1.4. Infectious Diseases
        • 5.2.1.5. Metabolic Disorders
        • 5.2.1.6. Others
      • 5.2.2. Global RNA Based Therapeutics by: Technology (Value)
        • 5.2.2.1. Inhibition
        • 5.2.2.2. Microarrays
        • 5.2.2.3. Labeling
        • 5.2.2.4. Purification
        • 5.2.2.5. QRT-PCR
        • 5.2.2.6. RNA Interference (RNAi) Technologies
        • 5.2.2.7. RNA Antisense Technologies
      • 5.2.3. Global RNA Based Therapeutics by: End User (Value)
        • 5.2.3.1. Research
        • 5.2.3.2. Therapeutics
        • 5.2.3.3. Diagnosis
      • 5.2.4. Global RNA Based Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global RNA Based Therapeutics (Price)
  • 6. RNA Based Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Quark Pharmaceuticals, Inc. (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alnylam Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dicerna Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Arbutus Biopharma (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Benitec Biopharma Limited (Australia)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genzyme Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Silence Therapeutics PLC (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sirnaomics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BioNTech AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CureVac AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global RNA Based Therapeutics Sale, by Application, Technology, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global RNA Based Therapeutics (Value)
      • 7.2.1. Global RNA Based Therapeutics by: Application (Value)
        • 7.2.1.1. Cardiovascular
        • 7.2.1.2. Kidney Diseases
        • 7.2.1.3. Oncology
        • 7.2.1.4. Infectious Diseases
        • 7.2.1.5. Metabolic Disorders
        • 7.2.1.6. Others
      • 7.2.2. Global RNA Based Therapeutics by: Technology (Value)
        • 7.2.2.1. Inhibition
        • 7.2.2.2. Microarrays
        • 7.2.2.3. Labeling
        • 7.2.2.4. Purification
        • 7.2.2.5. QRT-PCR
        • 7.2.2.6. RNA Interference (RNAi) Technologies
        • 7.2.2.7. RNA Antisense Technologies
      • 7.2.3. Global RNA Based Therapeutics by: End User (Value)
        • 7.2.3.1. Research
        • 7.2.3.2. Therapeutics
        • 7.2.3.3. Diagnosis
      • 7.2.4. Global RNA Based Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global RNA Based Therapeutics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. RNA Based Therapeutics: by Application(USD Million)
  • Table 2. RNA Based Therapeutics Cardiovascular , by Region USD Million (2015-2020)
  • Table 3. RNA Based Therapeutics Kidney Diseases , by Region USD Million (2015-2020)
  • Table 4. RNA Based Therapeutics Oncology , by Region USD Million (2015-2020)
  • Table 5. RNA Based Therapeutics Infectious Diseases , by Region USD Million (2015-2020)
  • Table 6. RNA Based Therapeutics Metabolic Disorders , by Region USD Million (2015-2020)
  • Table 7. RNA Based Therapeutics Others , by Region USD Million (2015-2020)
  • Table 8. RNA Based Therapeutics: by Technology(USD Million)
  • Table 9. RNA Based Therapeutics Inhibition , by Region USD Million (2015-2020)
  • Table 10. RNA Based Therapeutics Microarrays , by Region USD Million (2015-2020)
  • Table 11. RNA Based Therapeutics Labeling , by Region USD Million (2015-2020)
  • Table 12. RNA Based Therapeutics Purification , by Region USD Million (2015-2020)
  • Table 13. RNA Based Therapeutics QRT-PCR , by Region USD Million (2015-2020)
  • Table 14. RNA Based Therapeutics RNA Interference (RNAi) Technologies , by Region USD Million (2015-2020)
  • Table 15. RNA Based Therapeutics RNA Antisense Technologies , by Region USD Million (2015-2020)
  • Table 16. RNA Based Therapeutics: by End User(USD Million)
  • Table 17. RNA Based Therapeutics Research , by Region USD Million (2015-2020)
  • Table 18. RNA Based Therapeutics Therapeutics , by Region USD Million (2015-2020)
  • Table 19. RNA Based Therapeutics Diagnosis , by Region USD Million (2015-2020)
  • Table 20. South America RNA Based Therapeutics, by Country USD Million (2015-2020)
  • Table 21. South America RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 22. South America RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 23. South America RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 24. Brazil RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 25. Brazil RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 26. Brazil RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 27. Argentina RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 28. Argentina RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 29. Argentina RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 30. Rest of South America RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 31. Rest of South America RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 32. Rest of South America RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 33. Asia Pacific RNA Based Therapeutics, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 36. Asia Pacific RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 37. China RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 38. China RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 39. China RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 40. Japan RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 41. Japan RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 42. Japan RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 43. India RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 44. India RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 45. India RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 46. South Korea RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 47. South Korea RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 48. South Korea RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 49. Taiwan RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 50. Taiwan RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 51. Taiwan RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 52. Australia RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 53. Australia RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 54. Australia RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 56. Rest of Asia-Pacific RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 58. Europe RNA Based Therapeutics, by Country USD Million (2015-2020)
  • Table 59. Europe RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 60. Europe RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 61. Europe RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 62. Germany RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 63. Germany RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 64. Germany RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 65. France RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 66. France RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 67. France RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 68. Italy RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 69. Italy RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 70. Italy RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 71. United Kingdom RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 72. United Kingdom RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 73. United Kingdom RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 74. Netherlands RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 75. Netherlands RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 76. Netherlands RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 77. Rest of Europe RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 78. Rest of Europe RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 79. Rest of Europe RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 80. MEA RNA Based Therapeutics, by Country USD Million (2015-2020)
  • Table 81. MEA RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 82. MEA RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 83. MEA RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 84. Middle East RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 85. Middle East RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 86. Middle East RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 87. Africa RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 88. Africa RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 89. Africa RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 90. North America RNA Based Therapeutics, by Country USD Million (2015-2020)
  • Table 91. North America RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 92. North America RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 93. North America RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 94. United States RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 95. United States RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 96. United States RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 97. Canada RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 98. Canada RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 99. Canada RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 100. Mexico RNA Based Therapeutics, by Application USD Million (2015-2020)
  • Table 101. Mexico RNA Based Therapeutics, by Technology USD Million (2015-2020)
  • Table 102. Mexico RNA Based Therapeutics, by End User USD Million (2015-2020)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. RNA Based Therapeutics: by Application(USD Million)
  • Table 114. RNA Based Therapeutics Cardiovascular , by Region USD Million (2021-2026)
  • Table 115. RNA Based Therapeutics Kidney Diseases , by Region USD Million (2021-2026)
  • Table 116. RNA Based Therapeutics Oncology , by Region USD Million (2021-2026)
  • Table 117. RNA Based Therapeutics Infectious Diseases , by Region USD Million (2021-2026)
  • Table 118. RNA Based Therapeutics Metabolic Disorders , by Region USD Million (2021-2026)
  • Table 119. RNA Based Therapeutics Others , by Region USD Million (2021-2026)
  • Table 120. RNA Based Therapeutics: by Technology(USD Million)
  • Table 121. RNA Based Therapeutics Inhibition , by Region USD Million (2021-2026)
  • Table 122. RNA Based Therapeutics Microarrays , by Region USD Million (2021-2026)
  • Table 123. RNA Based Therapeutics Labeling , by Region USD Million (2021-2026)
  • Table 124. RNA Based Therapeutics Purification , by Region USD Million (2021-2026)
  • Table 125. RNA Based Therapeutics QRT-PCR , by Region USD Million (2021-2026)
  • Table 126. RNA Based Therapeutics RNA Interference (RNAi) Technologies , by Region USD Million (2021-2026)
  • Table 127. RNA Based Therapeutics RNA Antisense Technologies , by Region USD Million (2021-2026)
  • Table 128. RNA Based Therapeutics: by End User(USD Million)
  • Table 129. RNA Based Therapeutics Research , by Region USD Million (2021-2026)
  • Table 130. RNA Based Therapeutics Therapeutics , by Region USD Million (2021-2026)
  • Table 131. RNA Based Therapeutics Diagnosis , by Region USD Million (2021-2026)
  • Table 132. South America RNA Based Therapeutics, by Country USD Million (2021-2026)
  • Table 133. South America RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 134. South America RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 135. South America RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 136. Brazil RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 137. Brazil RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 138. Brazil RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 139. Argentina RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 140. Argentina RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 141. Argentina RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 142. Rest of South America RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 143. Rest of South America RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 144. Rest of South America RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 145. Asia Pacific RNA Based Therapeutics, by Country USD Million (2021-2026)
  • Table 146. Asia Pacific RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 147. Asia Pacific RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 148. Asia Pacific RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 149. China RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 150. China RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 151. China RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 152. Japan RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 153. Japan RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 154. Japan RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 155. India RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 156. India RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 157. India RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 158. South Korea RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 159. South Korea RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 160. South Korea RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 161. Taiwan RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 162. Taiwan RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 163. Taiwan RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 164. Australia RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 165. Australia RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 166. Australia RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 167. Rest of Asia-Pacific RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 168. Rest of Asia-Pacific RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 169. Rest of Asia-Pacific RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 170. Europe RNA Based Therapeutics, by Country USD Million (2021-2026)
  • Table 171. Europe RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 172. Europe RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 173. Europe RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 174. Germany RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 175. Germany RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 176. Germany RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 177. France RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 178. France RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 179. France RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 180. Italy RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 181. Italy RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 182. Italy RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 183. United Kingdom RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 184. United Kingdom RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 185. United Kingdom RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 186. Netherlands RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 187. Netherlands RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 188. Netherlands RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 189. Rest of Europe RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 190. Rest of Europe RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 191. Rest of Europe RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 192. MEA RNA Based Therapeutics, by Country USD Million (2021-2026)
  • Table 193. MEA RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 194. MEA RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 195. MEA RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 196. Middle East RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 197. Middle East RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 198. Middle East RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 199. Africa RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 200. Africa RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 201. Africa RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 202. North America RNA Based Therapeutics, by Country USD Million (2021-2026)
  • Table 203. North America RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 204. North America RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 205. North America RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 206. United States RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 207. United States RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 208. United States RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 209. Canada RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 210. Canada RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 211. Canada RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 212. Mexico RNA Based Therapeutics, by Application USD Million (2021-2026)
  • Table 213. Mexico RNA Based Therapeutics, by Technology USD Million (2021-2026)
  • Table 214. Mexico RNA Based Therapeutics, by End User USD Million (2021-2026)
  • Table 215. Research Programs/Design for This Report
  • Table 216. Key Data Information from Secondary Sources
  • Table 217. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global RNA Based Therapeutics: by Application USD Million (2015-2020)
  • Figure 5. Global RNA Based Therapeutics: by Technology USD Million (2015-2020)
  • Figure 6. Global RNA Based Therapeutics: by End User USD Million (2015-2020)
  • Figure 7. South America RNA Based Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific RNA Based Therapeutics Share (%), by Country
  • Figure 9. Europe RNA Based Therapeutics Share (%), by Country
  • Figure 10. MEA RNA Based Therapeutics Share (%), by Country
  • Figure 11. North America RNA Based Therapeutics Share (%), by Country
  • Figure 12. Global RNA Based Therapeutics share by Players 2020 (%)
  • Figure 13. Global RNA Based Therapeutics share by Players (Top 3) 2020(%)
  • Figure 14. Global RNA Based Therapeutics share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Quark Pharmaceuticals, Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 17. Quark Pharmaceuticals, Inc. (Israel) Revenue: by Geography 2020
  • Figure 18. Alnylam Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Alnylam Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Dicerna Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Dicerna Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Arbutus Biopharma (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Arbutus Biopharma (Canada) Revenue: by Geography 2020
  • Figure 24. Benitec Biopharma Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 25. Benitec Biopharma Limited (Australia) Revenue: by Geography 2020
  • Figure 26. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Genzyme Corporation (United States) Revenue: by Geography 2020
  • Figure 28. Silence Therapeutics PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Silence Therapeutics PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Sirnaomics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Sirnaomics, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. BioNTech AG (Germany) Revenue, Net Income and Gross profit
  • Figure 33. BioNTech AG (Germany) Revenue: by Geography 2020
  • Figure 34. CureVac AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. CureVac AG (Germany) Revenue: by Geography 2020
  • Figure 36. Global RNA Based Therapeutics: by Application USD Million (2021-2026)
  • Figure 37. Global RNA Based Therapeutics: by Technology USD Million (2021-2026)
  • Figure 38. Global RNA Based Therapeutics: by End User USD Million (2021-2026)
  • Figure 39. South America RNA Based Therapeutics Share (%), by Country
  • Figure 40. Asia Pacific RNA Based Therapeutics Share (%), by Country
  • Figure 41. Europe RNA Based Therapeutics Share (%), by Country
  • Figure 42. MEA RNA Based Therapeutics Share (%), by Country
  • Figure 43. North America RNA Based Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Quark Pharmaceuticals, Inc. (Israel)
  • Alnylam Pharmaceuticals, Inc. (United States)
  • Dicerna Pharmaceuticals, Inc. (United States)
  • Arbutus Biopharma (Canada)
  • Benitec Biopharma Limited (Australia)
  • Genzyme Corporation (United States)
  • Silence Therapeutics PLC (United Kingdom)
  • Sirnaomics, Inc. (United States)
  • BioNTech AG (Germany)
  • CureVac AG (Germany)
Additional players considered in the study are as follows:
Regulus Therapeutics, Inc. (United States) , Adhera Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 224 Pages 87 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global RNA Based Therapeutics Market Quantitative research analysis
Global RNA Based Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global RNA Based Therapeutics Market are Quark Pharmaceuticals, Inc. (Israel), Alnylam Pharmaceuticals, Inc. (United States), Dicerna Pharmaceuticals, Inc. (United States), Arbutus Biopharma (Canada), Benitec Biopharma Limited (Australia), Genzyme Corporation (United States), Silence Therapeutics PLC (United Kingdom), Sirnaomics, Inc. (United States), BioNTech AG (Germany) and CureVac AG (Germany) etc.
RNA based therapeutics have generated significant attention in recent years owing to their potential to treat a variety of chronic diseases such as diabetes, cancer, tuberculosis, and some cardiovascular conditions and rare diseases, and address targets that have proven to be intractable to antibody and small-molecule methodologies. RNA based therapeutics are poised to become successful commercial products, but extensive adoption across the bio pharmaceutical industry will likely take a few more years.

Know More About Global RNA Based Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Cancer Biological Therapy Comprehensive Study by Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Blood Cell Growth Factors), Application (Hospitals, Diagnostic Laboratories, Research &...
$ 3650
Ascites Comprehensive Study by Type (Exudate Ascites, Transudative Ascites), Application (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostics Centers, Others), Diagnosis (Angiography, Ultras...
$ 3650
Acute Intermittent Porphyria Comprehensive Study by Treatment (Gonadotropin-Releasing Hormone Analogues, Prophylactic Hematin Infusions, Others), Diagnosis (Blood Test, Urine Test, DNA Test, Serum Te...
$ 3450
Neurodegenerative Diseases Comprehensive Study by Application (Alzheimer's Disease, Huntington Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis), Drug Type (N-methyl-D-aspartate Receptor, ...
$ 3450
New Generation Implants Comprehensive Study by Type (Endosteal,, Subperiosteal,, Zygomatic.), Application (Orthopedic Implants, Cardiovascular Implants, Ocular Implants, Dental Implants), Raw Materia...
$ 3500
Bartter Syndrome Treatment Comprehensive Study by Type (Medication, Therapy), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Genes Types (LC12A1 Gene, KCNJ1 Gene, CLCNKB Gen...
$ 3750